Ultragenyx Pharmaceutical Inc.
60 Leveroni Court
Novato
California
94949
United States
Tel: 415-483-8800
Fax: 415-483-8810
Website: http://www.ultragenyx.com/careers/
Email: info@ultragenyx.com
447 articles about Ultragenyx Pharmaceutical Inc.
-
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Aug 17, 2022
8/17/2022
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultra-rare diseases, reported the grant of non-qualified stock options to purchase an aggregate of 19,020 shares of common stock of the company and 12,910 restricted stock units of the company’s common stock to two newly hired non-executive officers of the company.
-
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Aug 03, 2022
8/3/2022
Ultragenyx Pharmaceutical Inc. reported the grant of non-qualified stock options to purchase an aggregate of 27,500 shares of common stock of the company and 14,500 restricted stock units of the company’s common stock to two newly hired non-executive officers of the company.
-
Ultragenyx Reports Second Quarter 2022 Financial Results and Corporate Update
7/28/2022
Ultragenyx Pharmaceutical Inc. reported its financial results for the quarter ended June 30, 2022 and provided a corporate update for the year.
-
Ultragenyx to Host Conference Call for Second Quarter 2022 Financial Results and Corporate Update
7/25/2022
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases, today announced that it will host a conference call on Thursday, July 28, 2022, at 5:00pm ET to discuss its financial results and corporate update for the quarter ended June 30, 2022.
-
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - July 20, 2022
7/20/2022
Ultragenyx Pharmaceutical Inc. reported the grant of non-qualified stock options to purchase an aggregate of 10,240 shares of common stock of the company and 5,120 restricted stock units of the company’s common stock to one newly hired non-executive officer of the company.
-
The buyout comes on the heels of promising Phase I/II results from GTX-102, an antisense oligonucleotide candidate being developed to treat Angelman syndrome.
-
FOUNDATION FOR ANGELMAN SYNDROME THERAPEUTICS (FAST) ANNOUNCES SALE OF ITS SHARES IN GENETX TO ULTRAGENYX
7/18/2022
The Foundation for Angelman Syndrome Therapeutics (FAST) today announced that Ultragenyx Pharmaceutical Inc. has exercised its exclusive option to acquire GeneTx Biotherapeutics LLC, a biotechnology company founded and launched by FAST, and has closed on the acquisition.
-
Ultragenyx and GeneTx Provide Program Update on GTX-102 for Angelman Syndrome Including Promising Interim Data from Phase 1/2 Study
7/18/2022
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) and GeneTx Biotherapeutics LLC today provided a program update on GTX-102 for the treatment of Angelman syndrome (AS), including encouraging interim data from the open-label, dose-escalating Phase 1/2 study in pediatric patients who have a genetically confirmed diagnosis of full maternal UBE3A gene deletion.
-
Ultragenyx Announces Sale of a Portion of Future North American Royalties on Crysvita® (burosumab) for $500 Million to OMERS Capital Markets
7/14/2022
Ultragenyx Pharmaceutical Inc. today announced the sale of 30% of the company’s royalty interest from Kyowa Kirin Co.
-
n-Lorem Foundation and Ultragenyx United in Efforts to Help Nano-rare Patients
6/20/2022
Ultragenyx’s continued support bolsters n-Lorem’s non-profit model to provide personalized investigational medicines to nano-rare patients.
-
ION582 is uniquely formulated using RNA technology to provide relief to patients with Angelman syndrome, a rare disorder for which limited treatment options are available.
-
Ultragenyx to Present at Goldman Sachs Global Healthcare Conference
6/10/2022
Ultragenyx Pharmaceutical Inc. today announced that Emil D. Kakkis, M.D., Ph.D., the company's Chief Executive Officer and President, and Mardi Dier, the company’s Chief Financial Officer, will present at the Goldman Sachs Global Healthcare Conference on Thursday, June 16, 2022.
-
Ultragenyx to Present at Jefferies Global Healthcare Conference - June 01, 2022
6/1/2022
Ultragenyx Pharmaceutical Inc. announced that Emil D. Kakkis, M.D., Ph.D., the company's Chief Executive Officer and President, will present at the Jefferies Global Healthcare Conference on Wednesday, June 8, 2022, at 2:30 PM ET in New York.
-
Ultragenyx Announces Positive Longer-term Durability Data from Two Phase 1/2 Gene Therapy Studies at American Society of Gene & Cell Therapy (ASGCT) 2022 Annual Meeting
5/19/2022
Ultragenyx Pharmaceutical Inc. announced positive longer-term efficacy and safety data from Phase 1/2 studies of DTX401 for the potential treatment of Glycogen Storage Disease Type Ia and DTX301 for the potential treatment of Ornithine Transcarbamylase deficiency.
-
Ultragenyx Acquires Global Rights to AAV Gene Therapy ABO-102 for Sanfilippo Syndrome Type A (MPS IIIA) from Abeona Therapeutics
5/17/2022
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) and Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced an exclusive license agreement for AAV gene therapy ABO-102 (now UX111) for the treatment of Sanfilippo syndrome type A (MPS IIIA).
-
Ultragenyx Announces Upcoming Data Presentations at American Society of Gene & Cell Therapy (ASGCT) 2022 Annual Meeting
5/9/2022
Ultragenyx Pharmaceutical Inc. today announced that clinical, preclinical and manufacturing data from its investigational gene therapy programs will be presented at the American Society of Gene & Cell Therapy (ASGCT) 25th Annual Meeting, which will be held both in person and virtually May 16-19, 2022.
-
Ultragenyx Reports First Quarter 2022 Financial Results and Corporate Update
5/5/2022
Ultragenyx Pharmaceutical Inc. reported its financial results for the quarter ended March 31, 2022 and reaffirmed its financial guidance for the year.
-
Ultragenyx to Participate at BofA Securities 2022 Healthcare Conference
5/3/2022
Ultragenyx Pharmaceutical Inc. announced that Camille Bedrosian, M.D., the company’s Chief Medical Officer, and Mardi Dier, the company’s Chief Financial Officer, will present at the BofA Securities 2022 Healthcare Conference on Tuesday, May 10, 2022 at 5:40 PM ET.
-
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - May 03, 2022
5/3/2022
Ultragenyx Pharmaceutical Inc. reported the grant of non-qualified stock options to purchase an aggregate of 20,480 shares of common stock of the company and 11,620 restricted stock units of the company’s common stock to two newly hired non-executive officers of the company.
-
Ultragenyx to Host Conference Call for First Quarter 2022 Financial Results and Corporate Update
4/27/2022
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases, today announced that it will host a conference call on Thursday, May 5, 2022 at 5:00pm ET to discuss its financial results and corporate update for the quarter ended March 31, 2022.